Personalized radiation for men with newly diagnosed limited metastatic prostate cancer
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer
This project is testing whether adding targeted radiation to visible metastases helps men with a small number of newly diagnosed prostate cancer spread live longer or avoid further progression.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11143687 on NIH RePORTER |
What this research studies
You would join a phase 3 randomized trial run in North America as a sub-study of the international STAMPEDE platform, enrolling about 200 men. Participants are randomly assigned to receive metastasis-directed radiotherapy plus standard treatment or standard treatment alone, with regular conventional and molecular PET imaging. Doctors will collect tumor tissue and blood samples over time and use imaging and DNA sequencing to look for patterns that predict who benefits. The team will apply advanced radiomics, genomics, and bioinformatics to try to personalize which men should receive targeted radiation.
Who could benefit from this research
Good fit: Men newly diagnosed with de novo oligometastatic prostate cancer (a limited number of metastases) who are able to receive radiotherapy and standard prostate cancer treatment could be eligible.
Not a fit: Men with widespread metastatic disease, those who cannot tolerate radiotherapy, or those whose tumors lack predictive biomarkers identified by the study may not receive benefit from this approach.
Why it matters
Potential benefit: If successful, this could identify men with a small number of metastases who can be cured or have longer survival with targeted radiation and help personalize treatment choices.
How similar studies have performed: Smaller trials and retrospective studies have suggested metastasis-directed therapy can delay progression, but this is the first large phase 3 North American sub-study aiming to prove and personalize its benefit.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Spratt, Daniel Eidelberg — Case Western Reserve University
- Study coordinator: Spratt, Daniel Eidelberg
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.